Incyte Corporation vs Opthea Limited: SG&A Expense Trends

SG&A Expense Trends: Incyte Corporation vs Opthea Limited

In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent companies: Incyte Corporation and Opthea Limited, from 2014 to 2023.

Incyte Corporation, a leader in biopharmaceutical innovation, has seen its SG&A expenses grow by approximately 600% over the past decade, reflecting its aggressive expansion and investment in research and development. In contrast, Opthea Limited, a smaller player in the biotech arena, has experienced a more modest increase of around 1,500% in the same period, indicating its strategic scaling efforts.

Interestingly, 2023 marked a significant year for both companies, with Incyte's expenses peaking at over $1.16 billion, while Opthea's expenses reached $41.9 million. However, data for 2024 is incomplete, suggesting a need for cautious interpretation of future trends.